Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?
| Autor: | Catalina Santiago, P. de Lucas Ramos, Félix Gómez-Gallego, Alejandro Lucia, Fernando Bandrés, Zoraida Verde, Jm. Rodríguez González-Moro, S. López Martín |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Nicotine Genotype medicine.medical_treatment Pharmacology Serotonergic Cytochrome P-450 CYP2A6 Tratamiento médico Dopamine Uptake Inhibitors Internal medicine Genetic variation medicine Humans Pharmacology (medical) Receptor Serotonin 5-HT2A Nicotinic Agonists CYP2A6 Bupropion Genetic Association Studies Serotonin Plasma Membrane Transport Proteins Polymorphism Genetic Chemistry General Medicine Tobacco Use Disorder Middle Aged Tabaquismo Psychiatry and Mental health Pharmacogenetics Smoking cessation Female Smoking Cessation Serotonin Aryl Hydrocarbon Hydroxylases medicine.drug |
| Popis: | Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. The aim of this study was to evaluate the association between the effectiveness of treatment with nicotine or bupropion in heavy smokers (n=70), and 6 candidate polymorphisms in CYP2A6, 5-HTT and HTR2A genes. Analysis revealed a significant association between "favourable" genotype combination carriers (CYP2A6 "slow metabolizer" or 5HTT L-allele or HTR2A-1438GG) and nicotine treatment outcome (OR=2.69, 95% CI=1.28-5.64). Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment. 1.851 JCR (2014) Q3, 158/254 Pharmacology and pharmacy, 83/140 Psychiatry UEM |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|